tiprankstipranks
Trending News
More News >
Nanexa AB (SE:NANEXA)
:NANEXA
Sweden Market
Advertisement

Nanexa AB (NANEXA) Drug Pipeline

Compare
0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Nex-22A, A Prolonged Release Formulation Of Liraglutide
Type 2 Diabetes
Phase I
Recruiting
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
May 16, 2024
Nex-20A
Multiple Myeloma
Early Phase I
Completed
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
Nov 21, 2022
Nex-18A Injection, Azacitidine Injection
Acute Myeloid Leukemia (Aml), Myelodysplastic Syndromes (Mds), Chronic Myelomonocytic Leukemia (Cmml)
Phase I
Completed
Pharmacokinetics, Tolerability and Safety of NEX-18a
May 11, 2021

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Nanexa AB (NANEXA) have in its pipeline
      NANEXA is currently developing the following drugs: Nex-22A, A Prolonged Release Formulation Of Liraglutide, Nex-20A, Nex-18A Injection, Azacitidine Injection. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis